(43), which evaluated the impact of triple therapy (HAIC combined with TKIs and a PD-1 inhibitor) in patients with unresectable HCC (uHCC) stratified by Child-Pugh grade into CPA (grade A) and CPB (grade B) groups. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.